NIH currently evaluating SAB's rapid response platform to treat infectious disease
SIOUX FALLS, S.D. - Thursday, August 11th 2016 [ME NewsWire]
(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today that Phase I Clinical Trials are underway for its human antibody treatment (SAB-301) for MERS-CoV. The goal of the study–sponsored, funded and conducted by National Institutes of Health (NIH)–is to evaluate the dosage and safety of this new therapeutic.
Middle East Respiratory Syndrome (MERS) is a newly discovered, contagious and sometimes fatal respiratory illness, caused by a virus known as MERS coronavirus (MERS-CoV), with no known vaccines or treatments.
SAB produced SAB-301 utilizing its DiversitAb™ platform, which leverages transchromosomic cattle (Tc Bovine™). These cattle have been genetically designed to produce large amounts of human polyclonal antibodies (im
Read more »